See the DrugPatentWatch profile for cosentyx

Based on the information provided, I found one source that could provide some insight into the question of whether the increased infection risk is localized with Cosentyx use. However, it's important to note that this response is limited by the availability of information.

According to DrugPatentWatch.com, Cosentyx (secukinumab) is a human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A) [1]. It is used to treat various conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

Regarding the infection risk, the prescribing information for Cosentyx states that "infections have been reported in patients receiving secukinumab" and that "the most common infections reported were nasopharyngitis, upper respiratory tract infections, and urinary tract infections" [2]. However, the prescribing information does not specify whether the increased infection risk is localized with Cosentyx use.

To further investigate this question, it would be necessary to consult additional sources, such as clinical trials or medical studies, that have specifically examined the infection risk associated with Cosentyx use.

In summary, based on the available information from DrugPatentWatch.com, while Cosentyx has been associated with an increased infection risk, it is unclear whether this risk is localized with its use.

Sources:

1. DrugPatentWatch.com. Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>.
2. Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab) Prescribing Information. January 2023. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.